The medical treatment of overactive bladder, including current and future treatments

• Type: Another Publication in an International Scientific Journal
• Date: 2011

Authors

Athanasopoulos, A (Author) Other; Francisco Cruz (Author) FMUP

Journal

Title: Expert Opinion on Pharmacotherapy

Vol. 12

Pages: 1041-1055

ISSN: 1465-6566

Publisher: Taylor & Francis

Indexing

ISI Web of Knowledge - 9 Citations

Scopus - 13 Citations

Other information

Authenticus ID: P-002-RKQ

DOI: 10.1517/14656566.2011.554399

Abstract (EN): Areas covered: The current literature on the efficacy, suitability and safety of current and future treatments is reviewed based on a search of Medline/Pubmed for relevant articles published in English between 1980 and 2010. Expert opinion: Currently, antimuscarinic drugs are the cornerstone of OAB treatment; clinically recommended doses of these agents decrease the ability of the bladder to contract during the storage phase and so increase cystometric bladder capacity. In general, these agents are safe and have mild adverse effects. There is also evidence that, despite having different tolerability profiles, available drugs are well tolerated compared with placebo. Antimuscarinic agents, as a class, have similar efficacy. They offer substantial help in the alleviation of OAB symptoms, providing significant improvement to quality of life. Investigation to provide pharmacological alternatives whenever antimuscarinic drugs do not provide symptomatic relief or cause intolerable side effects is intense. Beta-adrenergic agents may be the next pharmacologic agents for OAB. However, many other areas of research may soon provide new pharmacological agents for OAB treatment.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 15